Wu, Bin <br/><br/>
Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.  [electronic resource] 

 -  Clinical therapeutics  Oct 2011 
 - 1446-55 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-114X 
<br/><br/><label>Standard No.: </label>10.1016/j.clinthera.2011.09.016  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>China<br/>Clinical Trials, Phase III as Topic<br/>Cost-Benefit Analysis<br/>Disease Progression<br/>Disease-Free Survival<br/>Endostatins--administration & dosage<br/>Humans<br/>Kaplan-Meier Estimate<br/>Lung Neoplasms--drug therapy<br/>Markov Chains<br/>Middle Aged<br/>Models, Economic<br/>Quality-Adjusted Life Years<br/>Randomized Controlled Trials as Topic<br/>Young Adult